Biologics

The authors of an article about relatively low biosimilar use by people with inflammatory bowel disease have suggestions for how to mitigage the nocebo effect.

Research published in JAMA Health Forum shows that biosimilar savings have not trickled down to out-of-pocket savings for patients.

Ten biosimilars to Humira are now on the market, but AbbVie’s Skyrizi and Rinvoq are soaking up revenues as Humira’s sales fall off.

Research underscores concerns that cost-sharing policies may contribute healthcare disparities.

But Amgen and Sandoz are in a patent fight over the launching of Sandoz's biosimilars to the bone-building drugs.

Zymfentra, with a price of $6,181.08 for two shots over four weeks, is approved as maintenance therapy for adults with ulcerative colitis and Crohn’s disease.

The market for Humira biosimilars may be shrinking as AbbVie works to boost prescriptions for its next-generation anti-inflammatories, Skyrizi (risankizumab) and Rinvoq (upadacitinib).

The submission is for the same indications, including Xolair’s recently approved indication IgE-mediated food allergy.

Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Acceptance is greater in oncology than in other specialties.